Indivior PLC Reports Q3 2025 Results and Optimizes Strategy

Indivior plc ( (INDV) ) has released its Q3 earnings. Here is a breakdown of the information Indivior plc presented to its investors.

Indivior PLC is a pharmaceutical company focused on developing treatments for opioid use disorder (OUD), aiming to transform OUD from a crisis to a recognized chronic disease. The company recently reported its financial results for the third quarter of 2025, highlighting a 2% year-over-year increase in total net revenue to $314 million and a significant 15% rise in SUBLOCADE net revenue to $219 million. Indivior also announced strategic initiatives, including the optimization of its Rest of World (ROW) business and the discontinuation of sales and marketing support for OPVEE.

The company’s financial performance was marked by a 14% increase in adjusted EBITDA to $120 million, driven by strong SUBLOCADE revenue growth and cost-saving measures. Indivior’s U.S. operations saw a 14% increase in SUBLOCADE net revenue, while its ROW operations experienced a 21% rise in SUBLOCADE net revenue. The company also launched a direct-to-consumer campaign to boost SUBLOCADE’s growth in the U.S.

Indivior’s strategic moves include exiting several non-U.S. markets and restructuring its R&D and Medical Affairs organizations. The company plans to redomicile to the U.S. and has expanded its presence in U.S. financial indices. These changes are expected to generate significant operating expense savings and improve cash generation.

Looking ahead, Indivior has raised its full-year 2025 financial guidance, anticipating total net revenue between $1,180 million and $1,220 million and adjusted EBITDA between $400 million and $420 million. The company remains focused on executing its Indivior Action Agenda, with plans to accelerate growth and enhance profitability in 2026.